FDA advisory committees
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription Drugs Advisory Committee slated to meet March 6-7, June 13-14 and Sept. 16-17, according to 1tentative 2003 advisory committee schedule published in Dec. 19 Federal Register. NDAC considered Rx-to-OTC switch applications for Schering-Plough's Claritin (loratadine) and AstraZeneca/Procter & Gamble's Prilosec (omeprazole), and discussed labeling and marketing for acetaminophen, aspirin and NSAIDs in 2002. CFSAN's Dietary Supplements Subcommittee of the Food Advisory Committee is slated to meet March 27-28 and Sept. 22-23, while the parent committee is scheduled to convene Feb. 24-26 and Aug. 18-20...